Progenics' Azedra wins FDA nod for rare NETs

FDA approved Azedra iobenguane I 131 from Progenics Pharmaceuticals Inc. (NASDAQ:PGNX) to treat unresectable, locally advanced or metastatic

Read the full 180 word article

User Sign In